Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 10/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30350708 | 0.85 | CHRM2 (0.49) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL19510572 | 0.85 | CHRM2 (0.49) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL15922822 | 0.80 | HTR1A (0.65) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL6940369 | 0.77 | MAOA (0.44) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL74678 | 0.76 | MAPT (0.59) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL1114869 | 0.76 | CHRM2 (0.46) | MAPTL3MBTL1 | |
| SCHEMBL7591530 | 0.75 | HTR1A (0.47) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL8995983 | 0.75 | HTR1A (0.52) | HTR1AADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL2197109 | 0.74 | MCHR1 (0.47) | MAPT | |
| SCHEMBL6215213 | 0.74 | MAPT (0.67) | HTR1AADRA1DADRA1AADRA1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128491-A1 | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans | RAO ALLA VENKATA RAMA (IN) | 2002-09-12 | — | — | US | disclosed |
| US-6403814-B1 | REACTING WITH GRIGNARD REAGENT COMPOUND HAVING CARBON SUBSTITUTED BY ACETYLENE GROUP, ARYL GROUP AND HYDROXYL GROUP, HYDROGENATING ACETYLENE MOIETY OF REACTION PRODUCT, CYCLIZING TO PROVIDE DI-ARYL TETRAHYDROFURAN | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128491-A1 | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans | TPMT, TPI1, GTF2I | HTR1A 751/4885ADRA1D 4212/4885ADRA1A 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.